This exclusion has been challenged due to an extraordinary philanthropic contribution from the Linda and Mike Mussallem Foundation to the Epstein Family Alzheimer’s Therapeutic Research Institute (Epstein ATRI) at the Keck School of Medicine of the University of Southern California. With this generous support, the landscape is rapidly evolving to offer expanded access both within the United States and internationally, revolutionizing the potential treatment landscape for Down syndrome individuals at risk of or living with Alzheimer’s.

The foundation’s leadership, Linda and Mike Mussallem, bring deeply personal insight to this mission, shaped by the lived experiences of their two brothers who were diagnosed with Down syndrome and later Alzheimer’s disease. Their commitment underscores the urgent necessity for more inclusive clinical trials that can yield therapies responsive to the specific neurobiological mechanisms at play in this population. This direct connection has fueled their advocacy and financial commitment to accelerate research that stands to impact not just Down syndrome individuals but potentially the general public’s understanding of Alzheimer’s.

Epstein ATRI, under the guidance of Dr. Michael Rafii—an internationally recognized neurologist and principal investigator for the Alzheimer’s Clinical Trials Consortium–Down Syndrome (ACTC-DS)—is spearheading a collaborative, multi-site clinical trial network poised to transform therapeutic development. The infusion of funding from the Mussallem Foundation ensures the expansion of domestic trial sites beyond the current robust network of 20 locations. Moreover, it secures the continuation of four international research hubs across Europe, including prestigious centers in Dublin, Cambridge, Paris, and Barcelona, which face research hiatus threats due to diminishing public funding streams.

The Mussallems have structured their gift with a matching component, effectively doubling the impact of investment and thereby fueling rapid scaling and optimization of clinical trial infrastructure. This approach accelerates the evaluation of emerging Alzheimer’s interventions for efficacy and safety tailored specifically to Down syndrome patients, a criterion historically overlooked in the broader Alzheimer’s research community.

Central to the scientific rationale for this focused research is the unique genetic basis underpinning Alzheimer’s disease in individuals with Down syndrome. This condition arises from trisomy 21—the presence of an extra copy of chromosome 21—which elevates expression of the amyloid precursor protein gene (APP). The overproduction of APP heightens amyloid-beta peptide accumulation in the brain, a pathological hallmark driving Alzheimer’s disease progression. Insights gleaned from studying amyloid dynamics in this genetically predisposed group could unlock novel therapeutic targets and biomarkers applicable more widely.

Down syndrome individuals have repeatedly demonstrated their capability as trial participants, dispelling myths about engagement and compliance challenges. Their involvement opens pathways to evaluating nuanced dosing regimens, therapeutic windows, and immunological responses that may differ substantially from the general population. Targeted drug development endeavors can therefore be calibrated with unprecedented precision.

Two pioneering trials highlight the promise of this initiative. The ALADDIN study explores donanemab, a monoclonal antibody developed by Eli Lilly already approved for treating Alzheimer’s disease in the general population. This trial investigates specific pharmacodynamics and pharmacokinetics adaptations necessary for efficacy and safety in Down syndrome patients, optimizing dosage and administration parameters. Meanwhile, the ABATE trial evaluates a novel vaccine approach that aims to proactively target amyloid burden, encompassing both typical Alzheimer’s patients and Down syndrome individuals in a single integrated protocol. This inclusive design maximizes data robustness and translational applicability.

The accelerated onset and advanced progression of Alzheimer’s in Down syndrome provide a natural model to study early biomarkers and pathophysiological changes, which closely mirror those observed in sporadic late-onset Alzheimer’s disease. This parallelism equips researchers with a unique vantage point to decipher disease trajectory, identify intervention points, and validate biomarker-enriched diagnostic tools.

Moreover, the broader scientific community benefits from this focused research since the genetic and mechanistic insights gathered from Down syndrome-associated Alzheimer’s are invaluable in unraveling the complex etiology of Alzheimer’s at large. Uncovering genetic modifiers, neuroinflammatory pathways, and amyloid processing peculiarities in this context feeds into the development of precision medicine strategies applicable across populations.

The catalytic role played by the Mussallem Foundation exemplifies how targeted philanthropic investment, informed by personal narratives and rigorous science, can trigger paradigm shifts in clinical research inclusivity. Their foundation, officially launched in 2024, channels resources into underfunded domains including congenital heart disease, integrative health solutions, and innovative Down syndrome healthcare. The collaboration with Epstein ATRI marks a milestone in bringing neglected patient cohorts into the forefront of cutting-edge therapeutic exploration.

The profound partnership between patients, caregivers, researchers, and funders is shifting the horizon towards a future where individuals with Down syndrome facing Alzheimer’s can access an array of scientifically robust, clinically validated, and personalized treatment options. This pioneering movement not only elevates patient care standards but also propels Alzheimer’s research into a new epoch of discovery, equity, and hope.

Subject of Research: Alzheimer’s disease in individuals with Down syndrome and expanded clinical trial access

Article Title: Unlocking Therapeutic Frontiers: Expanding Alzheimer’s Clinical Trials for Individuals with Down Syndrome

News Publication Date: 2024

Web References: https://www.mussallemfoundation.org/

Keywords: Alzheimer’s disease, Down syndrome, clinical trials, genetics, amyloid precursor protein, donanemab, vaccine research, neurodegenerative diseases, trisomy 21, therapeutic innovation

Down syndrome, caused by trisomy of chromosome 21, represents the most common genetic risk factor for Alzheimer’s disease, largely due to the overexpression of the amyloid precursor protein gene located on chromosome 21. This genetic anomaly leads to enhanced amyloid-beta aggregation, one of the hallmark pathologies of Alzheimer’s disease, resulting in an accelerated onset of neurodegeneration. Despite this strong link, diagnosing AD in individuals with DS has been challenging because traditional cognitive tests and imaging techniques are difficult to standardize across this population’s diverse cognitive baseline and often require costly, invasive methods.

The recent study led by Huber and colleagues addresses these challenges head-on by investigating plasma p-tau217, a phosphorylated form of the tau protein that accumulates abnormally in Alzheimer’s disease and correlates strongly with neurofibrillary tangle pathology. Tau phosphorylation at this specific site has emerged as one of the most promising fluid biomarkers in sporadic AD due to its high sensitivity and specificity for tau-related neurodegeneration. The team hypothesized that plasma p-tau217 could serve as an equally effective biomarker for individuals with DS, providing a less invasive and more accessible diagnostic tool.

The researchers conducted a large-scale analysis involving individuals with Down syndrome who underwent thorough clinical and neuropathological characterization. They measured plasma p-tau217 concentrations using highly sensitive immunoassays, correlating the levels with amyloid and tau PET imaging, cognitive assessments, and postmortem neuropathology findings. This multimodal approach enabled a rigorous validation of p-tau217 as a biomarker within this unique cohort, addressing variability related to age, sex, and clinical stage of disease.

Results revealed that plasma p-tau217 levels were markedly elevated in individuals with Down syndrome manifesting clinical signs of Alzheimer’s disease compared to cognitively stable DS participants and age-matched controls without DS. Moreover, these elevations correlated significantly with PET measures of amyloid and tau accumulation in the brain, reinforcing the biomarker’s ability to reflect underlying neuropathological processes. Intriguingly, plasma p-tau217 levels also predicted longitudinal cognitive decline, suggesting its utility not only as a diagnostic marker but also as a prognostic indicator for disease progression.

The implications of this research are vast, particularly in clinical trial design, where plasma p-tau217 could serve as a surrogate endpoint or a stratification tool for therapeutic interventions. Current trials aiming to slow or prevent AD in Down syndrome populations suffer from a lack of reliable, non-invasive biomarkers to identify individuals in the preclinical or prodromal stages. With the availability of plasma p-tau217 assays, researchers can more efficiently recruit and monitor participants, enabling earlier intervention and more accurate evaluation of treatment efficacy.

On a mechanistic level, the findings support the pathological cascade model of Alzheimer’s disease in Down syndrome, whereby amyloid accumulation precedes and facilitates tau phosphorylation and aggregation. The parallel between sporadic AD and DS-associated AD pathogenesis underscores the universality of p-tau217 as an indicator of neurofibrillary pathology, regardless of the genetic or idiopathic origins of the disease. This enhances the biomarker’s translational relevance and could facilitate cross-disease therapeutic strategies targeting tau pathology.

Further research is warranted to explore the temporal dynamics of plasma p-tau217 in relation to amyloid deposition and other biomarkers such as neurofilament light chain or glial fibrillary acidic protein. Understanding these relationships will refine the biomarker’s role in disease staging, helping to delineate the pre-symptomatic window for maximum therapeutic impact. Additionally, studies investigating the interplay between immune response, neuroinflammation, and p-tau217 levels could reveal novel insights into the complex pathophysiology of Alzheimer’s disease in Down syndrome.

An important aspect highlighted by the study is the feasibility and scalability of plasma p-tau217 measurement in clinical settings. Unlike expensive PET imaging or cerebrospinal fluid collection, blood sampling is minimally invasive, widely accessible, and cost-effective, making it ideally suited for large-scale screening in populations at high risk for Alzheimer’s disease. This advances the prospect of incorporating biomarker testing into routine clinical practice and facilitates personalized disease management.

Ethical considerations also come into play, especially in vulnerable populations such as individuals with intellectual disabilities. The use of blood-based biomarkers must be accompanied by appropriate counseling, informed consent, and support mechanisms to ensure that biomarker information enhances patient care without causing undue distress. Emphasizing patient-centric approaches will be vital as biomarker technologies move from research contexts to real-world application.

Notably, this research heralds a new era in Down syndrome medicine, where the focus is not merely on managing developmental challenges but also on anticipating and mitigating age-related neurodegeneration. The convergence of genomic insights, biomarker science, and advanced imaging fosters hope for earlier detection, improved prognosis, and ultimately, effective treatment of Alzheimer’s disease in this uniquely susceptible population.

The study also invites a broader reflection on the intersection of neurodevelopmental and neurodegenerative disorders, challenging traditional boundaries in neurology. By demonstrating the utility of AD biomarkers in Down syndrome, researchers underscore the continuum of brain pathologies and the shared molecular mechanisms underpinning different neurological conditions. This integrative perspective may catalyze novel therapeutic paradigms that address multiple facets of brain health simultaneously.

As the field advances, ongoing efforts must prioritize harmonization of biomarker assays, validation across diverse cohorts, and longitudinal studies tracking biomarker trajectories from childhood through aging in Down syndrome. Such comprehensive datasets will underpin robust clinical guidelines and regulatory approvals, enabling plasma p-tau217 to fulfill its promise as a critical tool in Alzheimer’s disease diagnosis and management.

In conclusion, the identification of plasma p-tau217 as a reliable biomarker of Alzheimer’s disease pathology in individuals with Down syndrome marks a significant milestone, heralding improved diagnostic accuracy and personalized care. This innovative approach bridges existing gaps in neurodegenerative disease detection and aligns with the broader trend towards biomarker-driven precision medicine. As research continues to unravel the complexities of Alzheimer’s disease, plasma p-tau217 stands poised to transform our understanding and treatment of this devastating illness in one of the most vulnerable populations.

Subject of Research: Plasma phosphorylated tau217 (p-tau217) as a biomarker for Alzheimer’s disease pathology in individuals with Down syndrome.

Article Title: Plasma p-tau217 as a biomarker of Alzheimer’s disease pathology in individuals with Down syndrome.

Article References:
Huber, H., Arranz, J., Arslan, B. et al. Plasma p-tau217 as a biomarker of Alzheimer’s disease pathology in individuals with Down syndrome. Nat Commun 16, 9900 (2025). https://doi.org/10.1038/s41467-025-65882-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-65882-x